bBHC

1:00 PM - 1:15 PM, Thursday, June 6, 2019 ・ Theater 2
bBHC Stem Cell Treatment & Research Institute which is called STRI has developed pluripotent stem cell without side effect which is called nEPS. We successfully differentiated the stem cell into a human pancreatic beta cell, neurocyte, hepatocyte, chondrocyte, osteoblast and kidney cell. STRI is the corporation to develop human tissue and organs. STRI has applied 470 patents related with nEPS over 146 countries, and 34 patents are registered in Korea, US, Russia, Isreal, Australia and Singapore. We use MSC to induce pluripotency only using natural compound with no artificial manipulation. This natural compound is called f002 which is originated from plant. And we have applied patents with this natural compound. We conduct researches for type 1& 2 diabetes, liver diseases, cancer and neuro diseases with nEPS. We are collaboration with Seoul National University, University of Michigan etc. We are interested in licensing out our core technology and research collaboratioin.
Ticker:
Not Provided.
Exchange:
Not Provided.
Company Type:
Company Website:
Company HQ State:
Not Provided.
Company HQ Country:
Korea - South Korea
Year Founded:
2012
Main Therapeutic Focus:
Lead Product in Development:
Differentiated cells from nEPS
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided.
Speaker
photo
CEO
bBHC